Phase I trial of two recombinant vaccines containing the 19kd carboxy terminal fragment of Plasmodium falciparum merozoite surface protein 1 (msp-119) and T helper epitopes of tetanus toxoid

W. A. Keitel; K. E. Kester; R. L. Atmar; A. C. White; N. H. Bond; C. A. Holland; U. Krzych; D. R. Palmer; A. Egan; C. Diggs; W. R. Ballou; B. F. Hall; D. Kaslow

doi:10.1016/S0264-410X(99)00221-2

Phase I trial of two recombinant vaccines containing the 19kd carboxy terminal fragment of Plasmodium falciparum merozoite surface protein 1 (msp-1₁₉) and T helper epitopes of tetanus toxoid

W. A. Keitel, K. E. Kester, R. L. Atmar, A. C. White, N. H. Bond, C. A. Holland, U. Krzych, D. R. Palmer, A. Egan, C. Diggs, W. R. Ballou, B. F. Hall, D. Kaslow

Research output: Contribution to journal › Article › peer-review

74 Scopus citations

Abstract

The safety and immunogenicity of 2 yeast-derived, blood-stage malaria vaccines were evaluated in a phase l trial. Healthy adults were given 2 or 3 doses of alum-adsorbed vaccine containing the 19 kDa carboxy-terminal fragment of the merozoite surface protein-1 (MSP-1₁₉) derived from the 3D7 or the FVO strain of Plasmodium falciparum fused to tetanus toxoid T-helper epitopes P30 and P2. The first 2 doses of MSP-1₁₉ were well tolerated. Hypersensitivity reactions occurred in 3 subjects after the third dose of MSP-1₁₉, including bilateral injection site reactions in 2 (one with generalized skin rash), and probable histamine-associated hypotension in 1. Serum antibody responses to MSP-1₁₉ occurred in 5/16, 9/16 and 0/8 subjects given 20 μg of MSP-1₁₉, 200 μg of MSP-1₁₉, and control vaccines (hepatitis B or Td), respectively. Both MSP-1₁₉ vaccines were immunogenic in humans, but changes in formulation will be necessary to improve safety and immunogenicity profiles. Copyright (C) 1999 Elsevier Science Ltd.

Original language	English (US)
Pages (from-to)	531-539
Number of pages	9
Journal	Vaccine
Volume	18
Issue number	5-6
DOIs	https://doi.org/10.1016/S0264-410X(99)00221-2
State	Published - Oct 14 1999
Externally published	Yes

Keywords

Malaria vaccines
Merozoite surface protein
Plasmodium falciparum

ASJC Scopus subject areas

Molecular Medicine
General Immunology and Microbiology
General Veterinary
Public Health, Environmental and Occupational Health
Infectious Diseases

Access to Document

10.1016/S0264-410X(99)00221-2

Cite this

Keitel, W. A., Kester, K. E., Atmar, R. L., White, A. C., Bond, N. H., Holland, C. A., Krzych, U., Palmer, D. R., Egan, A., Diggs, C., Ballou, W. R., Hall, B. F., & Kaslow, D. (1999). Phase I trial of two recombinant vaccines containing the 19kd carboxy terminal fragment of Plasmodium falciparum merozoite surface protein 1 (msp-1₁₉) and T helper epitopes of tetanus toxoid. Vaccine, 18(5-6), 531-539. https://doi.org/10.1016/S0264-410X(99)00221-2

Keitel, WA, Kester, KE, Atmar, RL, White, AC, Bond, NH, Holland, CA, Krzych, U, Palmer, DR, Egan, A, Diggs, C, Ballou, WR, Hall, BF & Kaslow, D 1999, 'Phase I trial of two recombinant vaccines containing the 19kd carboxy terminal fragment of Plasmodium falciparum merozoite surface protein 1 (msp-1₁₉) and T helper epitopes of tetanus toxoid', Vaccine, vol. 18, no. 5-6, pp. 531-539. https://doi.org/10.1016/S0264-410X(99)00221-2

@article{67a3a0864dd14b7a957c1fc18194e874,

title = "Phase I trial of two recombinant vaccines containing the 19kd carboxy terminal fragment of Plasmodium falciparum merozoite surface protein 1 (msp-119) and T helper epitopes of tetanus toxoid",

abstract = "The safety and immunogenicity of 2 yeast-derived, blood-stage malaria vaccines were evaluated in a phase l trial. Healthy adults were given 2 or 3 doses of alum-adsorbed vaccine containing the 19 kDa carboxy-terminal fragment of the merozoite surface protein-1 (MSP-119) derived from the 3D7 or the FVO strain of Plasmodium falciparum fused to tetanus toxoid T-helper epitopes P30 and P2. The first 2 doses of MSP-119 were well tolerated. Hypersensitivity reactions occurred in 3 subjects after the third dose of MSP-119, including bilateral injection site reactions in 2 (one with generalized skin rash), and probable histamine-associated hypotension in 1. Serum antibody responses to MSP-119 occurred in 5/16, 9/16 and 0/8 subjects given 20 μg of MSP-119, 200 μg of MSP-119, and control vaccines (hepatitis B or Td), respectively. Both MSP-119 vaccines were immunogenic in humans, but changes in formulation will be necessary to improve safety and immunogenicity profiles. Copyright (C) 1999 Elsevier Science Ltd.",

keywords = "Malaria vaccines, Merozoite surface protein, Plasmodium falciparum",

author = "Keitel, {W. A.} and Kester, {K. E.} and Atmar, {R. L.} and White, {A. C.} and Bond, {N. H.} and Holland, {C. A.} and U. Krzych and Palmer, {D. R.} and A. Egan and C. Diggs and Ballou, {W. R.} and Hall, {B. F.} and D. Kaslow",

note = "Funding Information: This research was supported by in part by contracts NO1-AI-25135, from the National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health; the United States Agency for International Development through interagency agreements with the Walter Reed Army Institute of Research and NIAID. The opinions or assertions contained herein are the private views of the authors and are not to be construed as official or as reflecting the views of the US Department of the Army or the Department of Defense. ",

year = "1999",

month = oct,

day = "14",

doi = "10.1016/S0264-410X(99)00221-2",

language = "English (US)",

volume = "18",

pages = "531--539",

journal = "Vaccine",

issn = "0264-410X",

publisher = "Elsevier BV",

number = "5-6",

}

TY - JOUR

T1 - Phase I trial of two recombinant vaccines containing the 19kd carboxy terminal fragment of Plasmodium falciparum merozoite surface protein 1 (msp-119) and T helper epitopes of tetanus toxoid

AU - Keitel, W. A.

AU - Kester, K. E.

AU - Atmar, R. L.

AU - White, A. C.

AU - Bond, N. H.

AU - Holland, C. A.

AU - Krzych, U.

AU - Palmer, D. R.

AU - Egan, A.

AU - Diggs, C.

AU - Ballou, W. R.

AU - Hall, B. F.

AU - Kaslow, D.

N1 - Funding Information: This research was supported by in part by contracts NO1-AI-25135, from the National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health; the United States Agency for International Development through interagency agreements with the Walter Reed Army Institute of Research and NIAID. The opinions or assertions contained herein are the private views of the authors and are not to be construed as official or as reflecting the views of the US Department of the Army or the Department of Defense.

PY - 1999/10/14

Y1 - 1999/10/14

N2 - The safety and immunogenicity of 2 yeast-derived, blood-stage malaria vaccines were evaluated in a phase l trial. Healthy adults were given 2 or 3 doses of alum-adsorbed vaccine containing the 19 kDa carboxy-terminal fragment of the merozoite surface protein-1 (MSP-119) derived from the 3D7 or the FVO strain of Plasmodium falciparum fused to tetanus toxoid T-helper epitopes P30 and P2. The first 2 doses of MSP-119 were well tolerated. Hypersensitivity reactions occurred in 3 subjects after the third dose of MSP-119, including bilateral injection site reactions in 2 (one with generalized skin rash), and probable histamine-associated hypotension in 1. Serum antibody responses to MSP-119 occurred in 5/16, 9/16 and 0/8 subjects given 20 μg of MSP-119, 200 μg of MSP-119, and control vaccines (hepatitis B or Td), respectively. Both MSP-119 vaccines were immunogenic in humans, but changes in formulation will be necessary to improve safety and immunogenicity profiles. Copyright (C) 1999 Elsevier Science Ltd.

AB - The safety and immunogenicity of 2 yeast-derived, blood-stage malaria vaccines were evaluated in a phase l trial. Healthy adults were given 2 or 3 doses of alum-adsorbed vaccine containing the 19 kDa carboxy-terminal fragment of the merozoite surface protein-1 (MSP-119) derived from the 3D7 or the FVO strain of Plasmodium falciparum fused to tetanus toxoid T-helper epitopes P30 and P2. The first 2 doses of MSP-119 were well tolerated. Hypersensitivity reactions occurred in 3 subjects after the third dose of MSP-119, including bilateral injection site reactions in 2 (one with generalized skin rash), and probable histamine-associated hypotension in 1. Serum antibody responses to MSP-119 occurred in 5/16, 9/16 and 0/8 subjects given 20 μg of MSP-119, 200 μg of MSP-119, and control vaccines (hepatitis B or Td), respectively. Both MSP-119 vaccines were immunogenic in humans, but changes in formulation will be necessary to improve safety and immunogenicity profiles. Copyright (C) 1999 Elsevier Science Ltd.

KW - Malaria vaccines

KW - Merozoite surface protein

KW - Plasmodium falciparum

UR - http://www.scopus.com/inward/record.url?scp=0032866084&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0032866084&partnerID=8YFLogxK

U2 - 10.1016/S0264-410X(99)00221-2

DO - 10.1016/S0264-410X(99)00221-2

M3 - Article

C2 - 10519944

AN - SCOPUS:0032866084

SN - 0264-410X

VL - 18

SP - 531

EP - 539

JO - Vaccine

JF - Vaccine

IS - 5-6

ER -